J. Menezes

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.3K citations

Non-small-cell Lung Cancer, Medicine, Pharmacology +6

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · ESMO Open · 2021 · 184 citations · Full text

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · Journal of Clinical Oncology · 2020 · 151 citations

Advanced Nsclc, Stage Iv/recurrent Nsclc, Pd-l1 Expression +11

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Evan J. Lipson, Hussein Tawbi, Dirk Schadendorf et al. · Journal of Clinical Oncology · 2021 · 149 citations

Surgical Oncology, Immune Regulation, Immunology +22

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

Georgina V. Long, F. Stephen Hodi, Evan J. Lipson et al. · NEJM Evidence · 2023 · 117 citations

Skin Cancer, Overall Survival, Medicine +15